609 related articles for article (PubMed ID: 15682420)
1. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.
Erdozain JG; Ruiz-Irastorza G; Egurbide MV; Aguirre C
Haematologica; 2004 Sep; 89(9):ECR34. PubMed ID: 15377486
[TBL] [Abstract][Full Text] [Related]
4. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
Kashif M; Qureshi A; Adil SN; Khurshid M
J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
[TBL] [Abstract][Full Text] [Related]
6. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.
Drobyski WR; Potluri J; Sauer D; Gottschall JL
Bone Marrow Transplant; 1996 Jun; 17(6):1093-9. PubMed ID: 8807120
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmune hemolytic anemia].
Berentsen S; Sundic T; Hervig T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2009 Nov; 129(21):2226-31. PubMed ID: 19898570
[TBL] [Abstract][Full Text] [Related]
9. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.
Trapè G; Fianchi L; Lai M; Laurenti L; Piscitelli R; Leone G; Pagano L
Haematologica; 2003 Feb; 88(2):223-5. PubMed ID: 12604415
[No Abstract] [Full Text] [Related]
10. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants.
Svahn J; Fioredda F; Calvillo M; Molinari AC; Micalizzi C; Banov L; Schmidt M; Caprino D; Marinelli D; Gallisai D; Dufour C
Br J Haematol; 2009 Apr; 145(1):96-100. PubMed ID: 19208098
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
[TBL] [Abstract][Full Text] [Related]
13. [Autoimmune hemolytic anemia].
Karasawa M
Nihon Rinsho; 2008 Mar; 66(3):520-3. PubMed ID: 18326320
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome.
Silvana B; Antonella LM; Basilia P; Trombetta D; Saija A; Salpietro C
Pediatr Transplant; 2007 Aug; 11(5):552-6. PubMed ID: 17631027
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
16. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
[TBL] [Abstract][Full Text] [Related]
17. A case report of refractory warm autoimmune hemolytic anemia treated with plasmapheresis and rituximab.
Aglieco F; Manickaratnam S; Bona R; Kaplan AA
Ther Apher Dial; 2008 Apr; 12(2):185-9. PubMed ID: 18387171
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for refractory childhood autoimmune hemolytic anemia.
Motto DG; Williams JA; Boxer LA
Isr Med Assoc J; 2002 Nov; 4(11):1006-8. PubMed ID: 12489491
[TBL] [Abstract][Full Text] [Related]
20. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
